fashion -WSS

fashion

author：fashion 2025-09-03 05:27:21 - browse：9416

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： A new study asks: Are we harming blood donors by taking blood?

WSS

Meta looks to target Twitter with a rival app called Threads

Option Care buys Amedisys in $3.6 billion home care deal

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

When is a doctor not a doctor? Try when patients address women doctors

Listen: Biogen's messy board & Laronde's data problem

Researchers tackle phage therapy hurdles for wider adoption

knowledge

fashion

hotspot

Continuity nursing helped my family in our darkest PICU moments

Make 'food is medicine' a key part of White House nutrition meeting

Anesthesiologist group: stop taking Ozempic before surgery

Australia's humpback populations rebound raising hopes of marine scientists

Malaria cases in Florida and Texas: Here’s what you need to know

Elevance, SCAN deals highlight health insurer acquisition scrutiny

New air purifier tech could be key to improving indoor air quality

Hospitals are piloting generative AI tools as regulators play catch

Anesthesiologist group: stop taking Ozempic before surgery

Did the public have the right to know Arthur Ashe had AIDS?

focus

As AI regulations shape up, health tech startups beg for clarity

Option Care buys Amedisys in $3.6 billion home care deal

Opioid cravings were reduced by anti

Secretariat’s lessons for human medicine

Congress may force more Covid

Measles policy set amid Florida outbreak alarms vaccine proponents

explore

leisure time

focus

focus